ChromaDex(US:CDXC)2025-11-04 21:01Financial Performance - Net sales increased 33% to $34.0 million, driven by a 44% increase in Tru Niagen® sales to $26.0 million[5] - Net income rose to $4.6 million, or $0.06 per share, compared to $1.9 million, or $0.02 per share, in the prior year[8] - Adjusted EBITDA increased by 120% to $6.4 million, up from $2.9 million in the same quarter last year[8] - Net sales for Q3 2025 reached $33.986 million, a 32.9% increase from $25.580 million in Q3 2024[22] - Gross profit for Q3 2025 was $21.928 million, up 35.5% from $16.240 million in Q3 2024[22] - Operating income for Q3 2025 increased to $4.236 million, compared to $1.602 million in Q3 2024, representing a 164.5% growth[22] - Net income for Q3 2025 was $4.578 million, significantly higher than $1.878 million in Q3 2024, marking a 143.5% increase[22] - Adjusted EBITDA for Q3 2025 was $6.361 million, up from $2.888 million in Q3 2024, representing a 120.5% increase[28] Cash Flow and Assets - Cash provided by operations for the nine months ended September 30, 2025, was $12.8 million, compared to $3.5 million in the prior year[9] - Cash and cash equivalents at the end of Q3 2025 totaled $64.290 million, up from $32.398 million at the end of Q3 2024, reflecting a 98.5% increase[26] - Total current assets increased to $93.616 million as of September 30, 2025, compared to $64.102 million at the end of 2024, a growth of 46.1%[24] - The company reported a net cash provided by operating activities of $12.825 million for the nine months ended September 30, 2025, compared to $3.526 million for the same period in 2024, a growth of 264.5%[26] Expenses and Margins - Gross margin improved by 100 basis points to 64.5%, attributed to product mix changes and lower-cost inventory[7] - Sales and marketing expenses as a percentage of net sales improved by 170 basis points to 25.8%[12] - Operating expenses for Q3 2025 totaled $17.692 million, a 20.0% increase from $14.638 million in Q3 2024[22] - Research and development expenses are expected to decrease as a percentage of net sales while continuing to increase in absolute dollars[11] Future Outlook - Full year 2025 net sales growth outlook reaffirmed at 25% to 30%, up from a previous range of 22% to 27%[10] Product and Market Development - The Company launched AboutNAD®, a digital platform for NAD+ research, enhancing brand visibility and scientific leadership[5] - The nationwide distribution network for Niagen Plus™ IV expanded to over 1,000 clinics, including more than 50 iCRYO locations[5]